The Problem
Immune checkpoint inhibitors (ICI) are a promising cancer treatment that remove inhibitory signals from the immune system allowing it to attack tumor cells. This comes with the risk of immune related adverse events (irAE) with potential ER visits and admission. This increases costs and morbidities.
Our Solution
Develop a risk score to identify ICI-utilizing patients at risk for a immune related adverse events.
Anticipated Impact
- Potential to reduce risk of a very promising cancer therapy.
- Reduced costs while providing better care for the patient.
